CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 21, 2020—Aalto Bio Reagents announced the availability of its range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers.
“Among all structural proteins of SARS-CoV-2, the S protein is the main antigenic component that is responsible for inducing host immune responses and neutralizing antibodies,” the company explained in a statement. “This makes it the principal focus of therapeutic and vaccine design for COVID-19.”
Pages: 1 2